HU222178B1
(en)
*
|
1993-08-10 |
2003-04-28 |
James Black Foundation Ltd. |
Gastrin and cck receptor ligands, preparation thereof and pharmaceutical compositions containing them
|
US5795907A
(en)
*
|
1994-05-27 |
1998-08-18 |
James Black Foundation Limited |
Gastin and CCK receptor ligands
|
MX9709874A
(en)
|
1995-06-06 |
1998-03-31 |
Pfizer |
Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors.
|
JP3314938B2
(en)
*
|
1995-06-06 |
2002-08-19 |
ファイザー・インコーポレーテッド |
Substituted N- (indole-2-carbonyl) -glycinamides and derivatives as glycogen phosphorylase inhibitors
|
KR100241643B1
(en)
|
1995-06-06 |
2000-03-02 |
디. 제이. 우드 |
Substituted N- (indole-2-carbonyl) -β-alanimamide and its derivatives for treating diabetes
|
GB9610974D0
(en)
*
|
1996-05-24 |
1996-07-31 |
Zeneca Ltd |
Herbicides
|
GB9708805D0
(en)
|
1997-05-01 |
1997-06-25 |
Smithkline Beecham Plc |
Compounds
|
TW527355B
(en)
|
1997-07-02 |
2003-04-11 |
Bristol Myers Squibb Co |
Inhibitors of farnesyl protein transferase
|
ATE377586T1
(en)
*
|
1997-12-23 |
2007-11-15 |
Inst Nat Sante Rech Med |
TRIPEPTIDYLPEPTIDASE INHIBITORS
|
US5955471A
(en)
*
|
1998-01-13 |
1999-09-21 |
Sk Corporation |
Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
|
GB9810876D0
(en)
|
1998-05-20 |
1998-07-22 |
Smithkline Beecham Plc |
Compounds
|
EP1114822A3
(en)
*
|
1998-06-03 |
2002-11-13 |
Cortech Inc. |
Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
|
JP2004517028A
(en)
*
|
1998-06-03 |
2004-06-10 |
コーテック インコーポレーテッド |
Indole and tetrahydroisoquinoline containing .ALPHA.-ketooxadiazoles as serine protease inhibitors
|
NZ511018A
(en)
|
1998-10-08 |
2003-09-26 |
Smithkline Beecham Plc |
Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
|
US6331541B1
(en)
|
1998-12-18 |
2001-12-18 |
Soo S. Ko |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
EP1158980B1
(en)
|
1998-12-18 |
2005-08-24 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
WO2000035452A1
(en)
|
1998-12-18 |
2000-06-22 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
EP1140834A1
(en)
|
1998-12-18 |
2001-10-10 |
Du Pont Pharmaceuticals Company |
Heterocyclic piperidines as modulators of chemokine receptor activity
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
US6897234B2
(en)
|
1999-12-17 |
2005-05-24 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
SE0000382D0
(en)
|
2000-02-07 |
2000-02-07 |
Astrazeneca Ab |
New process
|
MXPA02010452A
(en)
|
2000-05-11 |
2003-06-06 |
Bristol Myers Squibb Co |
Tetrahydroisoquinoline analogs useful as growth hormone secretagogues.
|
AU2001273129A1
(en)
|
2000-06-30 |
2002-01-14 |
Bristol-Myers Squibb Pharma Company |
N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
|
US6277877B1
(en)
|
2000-08-15 |
2001-08-21 |
Pfizer, Inc. |
Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
ES2282647T3
(en)
|
2002-06-14 |
2007-10-16 |
MERCK & CO., INC. |
INHIBITORS OF MITOTIC CINESINE.
|
JP4377323B2
(en)
|
2002-06-14 |
2009-12-02 |
メルク エンド カムパニー インコーポレーテッド |
Mitotic kinesin inhibitor
|
ES2319429T3
(en)
|
2003-08-15 |
2009-05-07 |
MERCK & CO., INC. |
INHIBITORS OF MITOTIC CINESINE.
|
US7666862B2
(en)
|
2003-08-15 |
2010-02-23 |
Merck & Co., Inc. |
Mitotic Kinesin Inhibitors
|
WO2005017190A2
(en)
|
2003-08-15 |
2005-02-24 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
FR2876102A1
(en)
*
|
2004-10-04 |
2006-04-07 |
Solvay |
ENANTIOPUR HETEROCYCLIC COMPOUND
|
JP5121346B2
(en)
*
|
2007-08-07 |
2013-01-16 |
国立大学法人 長崎大学 |
Optically active proline ester derivative and method for producing N-formyl optically active proline derivative
|
CN102812003B
(en)
*
|
2009-12-18 |
2015-01-21 |
欧洲筛选有限公司 |
Pyrrolidine Or Thiazolidine Carboxylic Acid Derivatives, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disordersas As Agonists Of G- Protein Coupled Receptor 43 (GPR43)
|
EA023259B1
(en)
|
2011-01-04 |
2016-05-31 |
Новартис Аг |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
US9108951B2
(en)
|
2011-10-14 |
2015-08-18 |
Bristol-Myers Squibb Company |
Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
|
ES2625256T3
(en)
|
2011-10-14 |
2017-07-19 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline compounds substituted as XIA factor inhibitors
|
IN2014CN02805A
(en)
|
2011-10-14 |
2015-07-03 |
Bristol Myers Squibb Co |
|
US9388199B2
(en)
|
2012-06-28 |
2016-07-12 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
JP6155332B2
(en)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
Pyrrolidine derivatives and their use as complement pathway regulators
|
CN104640855B
(en)
|
2012-06-28 |
2017-08-29 |
诺华股份有限公司 |
Complement is by way of conditioning agent and application thereof
|
WO2014002051A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
US9464081B2
(en)
|
2012-06-28 |
2016-10-11 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
WO2014009833A2
(en)
|
2012-07-12 |
2014-01-16 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
US9403774B2
(en)
|
2012-10-12 |
2016-08-02 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
KR102143257B1
(en)
|
2012-10-12 |
2020-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Crystalline forms of a factor xia inhibitor
|
US9315519B2
(en)
|
2012-10-12 |
2016-04-19 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
|
ES2712699T3
(en)
|
2013-03-25 |
2019-05-14 |
Bristol Myers Squibb Co |
Tetrahydroisoquinolines containing substituted azoles as inhibitors of factor XIa
|
US9770435B2
(en)
|
2013-11-27 |
2017-09-26 |
Ogeda Sa |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
TWI688564B
(en)
|
2014-01-31 |
2020-03-21 |
美商必治妥美雅史谷比公司 |
Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
|
NO2760821T3
(en)
|
2014-01-31 |
2018-03-10 |
|
|
AU2015223075A1
(en)
|
2014-02-25 |
2016-09-01 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of complement mediated disorders
|
CN107074821B
(en)
|
2014-09-04 |
2020-05-22 |
百时美施贵宝公司 |
Diamide macrocycles as FXIA inhibitors
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
ES2809208T3
(en)
|
2015-06-25 |
2021-03-03 |
Promega Corp |
Thienopyrrole compounds and uses thereof as luciferase inhibitors from Oplophorus
|
AR105809A1
(en)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
AR106018A1
(en)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
AR105808A1
(en)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
WO2017035409A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
AU2017290593A1
(en)
|
2016-06-27 |
2019-01-03 |
Achillion Pharmaceuticals, Inc. |
Quinazoline and indole compounds to treat medical disorders
|
IL303696A
(en)
|
2017-03-01 |
2023-08-01 |
Achillion Pharmaceuticals Inc |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
WO2018160892A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for treatment of medical disorders
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
MX2020003242A
(en)
|
2017-09-22 |
2020-09-18 |
Jubilant Epipad LLC |
Heterocyclic compounds as pad inhibitors.
|
IL272667B
(en)
|
2017-10-18 |
2022-09-01 |
Jubilant Epipad LLC |
Imidazo-pyridine compounds as pad inhibitors
|
US11629135B2
(en)
|
2017-11-06 |
2023-04-18 |
Jubilant Prodell Llc |
Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
|
WO2019102494A1
(en)
|
2017-11-24 |
2019-05-31 |
Jubilant Biosys Limited |
Heterocyclic compounds as prmt5 inhibitors
|
CN112105610B
(en)
|
2018-03-13 |
2024-01-26 |
朱比连特普罗德尔有限责任公司 |
Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
|
GB201810486D0
(en)
*
|
2018-06-26 |
2018-08-08 |
Imperial Innovations Ltd |
Natural killer cells
|
EP3841086A4
(en)
|
2018-08-20 |
2022-07-27 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
US11814391B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
WO2020051538A1
(en)
|
2018-09-06 |
2020-03-12 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
KR20210093855A
(en)
|
2018-09-25 |
2021-07-28 |
아칠리온 파르마세우티칼스 인코포레이티드 |
Conformational forms of complement factor D inhibitors
|
WO2023164238A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Regents Of The University Of Minnesota |
Protease inhibitors
|